Summit Therapeutics (SMMT) EBT (2016 - 2024)
Historic EBT for Summit Therapeutics (SMMT) over the last 8 years, with Q4 2024 value amounting to -$65.6 million.
- Summit Therapeutics' EBT fell 8122.89% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$183.2 million, marking a year-over-year decrease of 9497.02%. This contributed to the annual value of -$234.7 million for FY2024, which is 6183.55% up from last year.
- As of Q4 2024, Summit Therapeutics' EBT stood at -$65.6 million, which was down 8122.89% from -$60.8 million recorded in Q3 2024.
- Summit Therapeutics' 5-year EBT high stood at -$7.4 million for Q1 2020, and its period low was -$65.6 million during Q4 2024.
- Its 4-year average for EBT is -$32.5 million, with a median of -$20.5 million in 2023.
- As far as peak fluctuations go, Summit Therapeutics' EBT plummeted by 2096.81% in 2023, and later tumbled by 19685.73% in 2024.
- Quarter analysis of 4 years shows Summit Therapeutics' EBT stood at -$7.4 million in 2020, then tumbled by 172.58% to -$20.3 million in 2022, then crashed by 78.38% to -$36.2 million in 2023, then tumbled by 81.23% to -$65.6 million in 2024.
- Its last three reported values are -$65.6 million in Q4 2024, -$60.8 million for Q3 2024, and -$36.2 million during Q4 2023.